Manejo de hemorragia asociada a anticoagulantes orales directos: estado actual de las estrategias de reversión / Management of bleeding associated with direct oral anticoagulants: update on reversal strategies
Rev. méd. Chile
; 147(1): 73-82, 2019. tab, graf
Artigo
em Espanhol
| LILACS
| ID: biblio-991375
Biblioteca responsável:
CL1.1
ABSTRACT
Direct oral anticoagulants (DOACs), including the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban have at least comparable efficacy as vitamin K antagonists along with a better safety profile, reflected by a lower incidence of intracranial hemorrhage. Specific reversal agents have been developed in recent years. Namely, idarucizumab, a specific antidote for dabigatran, is currently approved in most countries. Andexanet, which reverses factor Xa inhibitors, has been recently approved by the FDA, and ciraparantag, a universal antidote targeted to reverse all DOACs, is still under investigation. In this review we provide an update on the pharmacology of DOACs, the risk of hemorrhagic complications associated with their use, the measurement of their anticoagulant effect and the reversal strategies in case of DOAC-associated bleeding.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
LILACS
Assunto principal:
Fatores de Coagulação Sanguínea
/
Antitrombinas
/
Anticorpos Monoclonais Humanizados
/
Hemorragia
Tipo de estudo:
Estudo de etiologia
/
Fatores de risco
Limite:
Humanos
Idioma:
Espanhol
Revista:
Rev. méd. Chile
Assunto da revista:
Medicina
Ano de publicação:
2019
Tipo de documento:
Artigo
País de afiliação:
Canadá
/
Chile
Instituição/País de afiliação:
Hospital Guillermo Grant Benavente/CL
/
Pontificia Universidad Católica de Chile/CL
/
Queen's University/CA